BioSpace News Archive

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7 a.m. ET.

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced its participation in the following upcoming investor and scientific conferences.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of September.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced positive interim results from a Phase 2a positron emission tomography imaging-based clinical trial of PLN-74809, an oral small molecule dual selective inhibitor of αvβ6/αvβ1, in patients with idiopathic pulmonary fibrosis.

Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

Centene announced two key appointments, further aligning our organization structure and operating model with our strategic priorities and accelerating impact to the business and value creation.

CollPlant announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright 23rd Annual Global Investment Conference which will be held virtually on September 13-15, 2021.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced results of a new preclinical study demonstrating opaganib’s [1] efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis model.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences.